Incyte (INCY) PT Lifted to $126 at BMO Capital Following Competitor Set-Back
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Incyte (INCY) Seen Back of Gilead's (GILD) Takeover Target List Following Disappointing Momelotinib Data - Leerink
November 17, 2016 8:24 AM ESTLeerink Partners analyst Geoffrey Porges says Incyte (NASDAQ: INCY) is back on the list of Gilead Sciences' (NASDAQ: GILD) takeover targets after Gilead's disappointing phase III data for their JAK 1/2 inhibitor momelotinib in myelofibrosis.
"One consequence of this disappointment, however, is that it does restore INCY to the list of... More
Incyte (INCY) PT Bumped to $115 at Leerink as Gilead's (GILD) Momelotinib Disappoints
November 17, 2016 8:12 AM ESTLeerink Partners analyst Michael Schmidt reiterated an Outperform rating and bumped his price target on Incyte (NASDAQ: INCY) to $115.00 (from $101.00) as Gilead Sciences' (NASDAQ: GILD) momelotinib disappoints.
Schmidt commented, "Today GILD (MP) reported top-line results from two Phase III... More
